BSP:I2TC34 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BSP:I2TC34 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Intra-Cellular Therapies's enterprise value is R$2,075 Mil. Intra-Cellular Therapies's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was R$2,856 Mil. Therefore, Intra-Cellular Therapies's EV-to-Revenue for today is 0.73.
The historical rank and industry rank for Intra-Cellular Therapies's EV-to-Revenue or its related term are showing as below:
During the past 12 years, the highest EV-to-Revenue of Intra-Cellular Therapies was 61490.30. The lowest was 10.03. And the median was 618.09.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-09-24), Intra-Cellular Therapies's stock price is R$71.15. Intra-Cellular Therapies's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was R$28.98. Therefore, Intra-Cellular Therapies's PS Ratio for today is 2.46.
The historical data trend for Intra-Cellular Therapies's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intra-Cellular Therapies Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-Revenue | Get a 7-Day Free Trial | - | 85.68 | 47.72 | 17.85 | 13.89 |
Intra-Cellular Therapies Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
EV-to-Revenue | Get a 7-Day Free Trial | 15.35 | 10.85 | 13.89 | 12.27 | 11.06 |
For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Intra-Cellular Therapies's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Intra-Cellular Therapies's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 2074.701 | / | 2855.629 | |
= | 0.73 |
Intra-Cellular Therapies's current Enterprise Value is R$2,075 Mil.
Intra-Cellular Therapies's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$2,856 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intra-Cellular Therapies (BSP:I2TC34) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Intra-Cellular Therapies's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 71.15 | / | 28.976 | |
= | 2.46 |
Intra-Cellular Therapies's share price for today is R$71.15.
Intra-Cellular Therapies's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$28.98.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Intra-Cellular Therapies's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.